Investor Center
Investor Center

News Release

Printer Friendly Version View printer-friendly version
<< Back
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March
Download PDF Download PDF

DUBLIN, March 6, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. 

  • Cowen and Company 38th Annual Healthcare Conference in Boston, MA on Tuesday, March 13, 2018 at 8:00 a.m. EDT / 12:00 p.m. GMTBruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.
  • Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 14, 2018 at 8:00 a.m. EDT / 12:00 p.m. GMTMatt Young, executive vice president and chief financial officer, will provide an overview of the company and a business and financial update.

A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S.  For country-specific product information, please visit  For more information, please visit and follow us on Twitter at @JazzPharma.

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)


Cision View original content with multimedia:

SOURCE Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Contacts: Investors: Kathee Littrell, Vice President, Investor Relations, Ireland, +353 1 634 7887, U.S., +1 650 496 2717, or Media: Jacqueline Kirby, Vice President, Corporate Affairs & Government Relations, Ireland, +353 1 697 2141, U.S., +1 215 867 4910